Skip to main content
TipRanks
Go Ultimate75% OFF
Adcendo ApS logo

Adcendo ApS: Valuation, Funding & Investors

Nordre Fasanvej 215 Frederiksberg, Capital Region of Denmark 2000, DKhttps://adcendo.com/Therapeutics

Adcendo ApS is a biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a clinical ADC pipeline including programs ADCE-T02 (Tissue Factor), ADCE-D01 (uPARAP), and ADCE-B05, focusing on dose escalation and expansion studies across multiple tumor indications.

Leadership & Board

Current Number of Employees
68
Current LinkedIn Followers
11,632

Latest Estimated Valuation

Total Amount Raised
$75M
Total Funding Rounds
1
Latest Funding Amount
$75M
Latest Funding Round
Series C

Employee Trend

Adcendo ApS had 68 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.

68Latest Employee Count
0(0.00%)Week-Over-Week Change
020406080Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Social Trend

Adcendo ApS had 11,632 followers as of November 9, 2026. The number of followers increased by 30 (0.26%) week-over-week.

11,632Latest Followers Count
30(0.26%)Week-Over-Week Change
05,00010,00015,00020,000Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026Oct 26, 2026Nov 09, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Apr 14, 2026Series C$75.00M―

Investors

Investor NameFunding Round
Jeito CapitalSeries C
Vida VenturesSeries C
BPI FranceSeries C
EIFOSeries C

Similar Companies

A snapshot of private companies similar to Adcendo ApS, helping you discover and navigate related company profiles.

Related News and Analysis